BibTex format

author = {Patch, A-M and Christie, EL and Etemadmoghadam, D and Garsed, DW and George, J and Fereday, S and Nones, K and Cowin, P and Alsop, K and Bailey, PJ and Kassahn, KS and Newell, F and Quinn, MCJ and Kazakoff, S and Quek, K and Wilhelm-Benartzi, C and Curry, E and Leong, HS and Hamilton, A and Mileshkin, L and Au-Yeung, G and Kennedy, C and Hung, J and Chiew, Y-E and Harnett, P and Friedlander, M and Quinn, M and Pyman, J and Cordner, S and O'Brien, P and Leditschke, J and Young, G and Strachan, K and Waring, P and Azar, W and Mitchell, C and Traficante, N and Hendley, J and Thorne, H and Shackleton, M and Miller, DK and Arnau, GM and Tothill, RW and Holloway, TP and Semple, T and Harliwong, I and Nourse, C and Nourbakhsh, E and Manning, S and Idrisoglu, S and Bruxner, TJC and Christ, AN and Poudel, B and Holmes, O and Anderson, M and Leonard, C and Lonie, A and Hall, N and Wood, S and Taylor, DF and Xu, Q and Fink, JL and Waddell, N and Drapkin, R and Stronach, E and Gabra, H and Brown, },
doi = {10.1038/nature14410},
journal = {Nature},
pages = {489--494},
title = {Whole-genome characterization of chemoresistant ovarian cancer},
url = {},
volume = {521},
year = {2015}

RIS format (EndNote, RefMan)

AB - Patients with high-grade serous ovarian cancer (HGSC) have experienced little improvement in overall survival, and standard treatment has not advanced beyond platinum-based combination chemotherapy, during the past 30 years. To understand the drivers of clinical phenotypes better, here we use whole-genome sequencing of tumour and germline DNA samples from 92 patients with primary refractory, resistant, sensitive and matched acquired resistant disease. We show that gene breakage commonly inactivates the tumour suppressors RB1, NF1, RAD51B and PTEN in HGSC, and contributes to acquired chemotherapy resistance. CCNE1 amplification was common in primary resistant and refractory disease. We observed several molecular events associated with acquired resistance, including multiple independent reversions of germline BRCA1 or BRCA2 mutations in individual patients, loss of BRCA1 promoter methylation, an alteration in molecular subtype, and recurrent promoter fusion associated with overexpression of the drug efflux pump MDR1.
AU - Patch,A-M
AU - Christie,EL
AU - Etemadmoghadam,D
AU - Garsed,DW
AU - George,J
AU - Fereday,S
AU - Nones,K
AU - Cowin,P
AU - Alsop,K
AU - Bailey,PJ
AU - Kassahn,KS
AU - Newell,F
AU - Quinn,MCJ
AU - Kazakoff,S
AU - Quek,K
AU - Wilhelm-Benartzi,C
AU - Curry,E
AU - Leong,HS
AU - Hamilton,A
AU - Mileshkin,L
AU - Au-Yeung,G
AU - Kennedy,C
AU - Hung,J
AU - Chiew,Y-E
AU - Harnett,P
AU - Friedlander,M
AU - Quinn,M
AU - Pyman,J
AU - Cordner,S
AU - O'Brien,P
AU - Leditschke,J
AU - Young,G
AU - Strachan,K
AU - Waring,P
AU - Azar,W
AU - Mitchell,C
AU - Traficante,N
AU - Hendley,J
AU - Thorne,H
AU - Shackleton,M
AU - Miller,DK
AU - Arnau,GM
AU - Tothill,RW
AU - Holloway,TP
AU - Semple,T
AU - Harliwong,I
AU - Nourse,C
AU - Nourbakhsh,E
AU - Manning,S
AU - Idrisoglu,S
AU - Bruxner,TJC
AU - Christ,AN
AU - Poudel,B
AU - Holmes,O
AU - Anderson,M
AU - Leonard,C
AU - Lonie,A
AU - Hall,N
AU - Wood,S
AU - Taylor,DF
AU - Xu,Q
AU - Fink,JL
AU - Waddell,N
AU - Drapkin,R
AU - Stronach,E
AU - Gabra,H
AU - Brown,R
AU - Jewell,A
AU - Nagaraj,SH
AU - Markham,E
AU - Wilson,PJ
AU - Ellul,J
AU - McNally,O
AU - Doyle,MA
AU - Vedururu,R
AU - Stewart,C
AU - Lengyel,E
AU - Pearson,JV
AU - Waddell,N
AU - deFazio,A
AU - Grimmond,SM
AU - Bowtell,DDL
DO - 10.1038/nature14410
EP - 494
PY - 2015///
SN - 0028-0836
SP - 489
TI - Whole-genome characterization of chemoresistant ovarian cancer
T2 - Nature
UR -
UR -
UR -
VL - 521
ER -